News
BLCO
16.58
-5.26%
-0.92
Eye Care Giant Posts $5.1 Billion in Revenue as One Investor Builds Major Position
The Motley Fool · 14h ago
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Evotec AG (EVO), Shoulder Innovations, Inc. (SI) and Bausch + Lomb Corporation (BLCO)
TipRanks · 1d ago
Teladoc (TDOC) Surges 5.1%: Is This an Indication of Further Gains?
NASDAQ · 1d ago
A Look At Bausch + Lomb (NYSE:BLCO) Valuation As Glaucoma Pipeline Webinar Draws Fresh Attention
Simply Wall St · 2d ago
Bausch + Lomb Launches R&D Webinar Series Spotlighting Glaucoma Pipeline
TipRanks · 3d ago
Weekly Report: what happened at BLCO last week (0302-0306)?
Weekly Report · 3d ago
Stocks in play: Bausch + Lomb Corporation
Barchart · 3d ago
Bausch Lomb LUMIFY Research Highlights Redness Trend And Potential Valuation Upside
Simply Wall St · 5d ago
Integra LifeSciences, GE HealthCare, Bausch + Lomb, ICU Medical, and Universal Health Services Shares Are Falling, What You Need To Know
Barchart · 6d ago
Morgan Stanley Sticks to Its Buy Rating for Bausch + Lomb Corporation (BLCO)
TipRanks · 03/05 11:36
Insider Power Move: Bausch + Lomb Director Makes Bold New Share Grab
TipRanks · 03/05 02:07
Most and least shorted mid-to mega-cap healthcare stocks in February
Seeking Alpha · 03/04 14:35
Weekly Report: what happened at BLCO last week (0223-0227)?
Weekly Report · 03/02 10:00
FedEx, EssilorLuxottica sued by customers for tariff refunds
Seeking Alpha · 02/28 19:16
Assessing Bausch + Lomb (BLCO) Valuation After Strong Q4 Growth And Vision 27 Margin Progress
Simply Wall St · 02/28 11:29
Trump Trade: L’Oreal, Bausch + Lomb sue for Trump tariff refunds
TipRanks · 02/25 15:05
Is Expert Backing Of LUMIFY’s Safety Profile Quietly Shaping Bausch + Lomb’s Consumer Strategy (BLCO)?
Simply Wall St · 02/25 12:31
5 Revealing Analyst Questions From Bausch + Lomb’s Q4 Earnings Call
Barchart · 02/25 03:54
Insiders Make Bold Moves as Bausch + Lomb Directors Boost Their Stakes
TipRanks · 02/25 02:03
L’Oreal, Bausch + Lomb sue for Trump tariff refunds, Reuters reports
TipRanks · 02/24 21:00
More
Webull provides a variety of real-time BLCO stock news. You can receive the latest news about Bausch + Lomb Corporation through multiple platforms. This information may help you make smarter investment decisions.
About BLCO
Bausch + Lomb Corporation is an eye health company. It operates through three segments: Vision Care, Pharmaceuticals, and Surgical. Vision Care segment includes both a contact lens and a consumer eye care business that consists of contact lens care products, over-the-counter eye drops and eye vitamins. Pharmaceuticals segment consists of generic pharmaceutical products for post-operative treatments and treatments for a number of eye conditions, such as glaucoma, eye inflammation, ocular hypertension, dry eyes and retinal diseases. Surgical segment consists of medical device equipment, consumables, instruments and technologies for the treatment of cataracts, corneal and vitreous and retinal eye conditions, which includes delivery systems, phacoemulsification equipment and other surgical instruments and devices for cataract surgery. Its brands consist of PreserVision, Biotrue, Artelac, Alaway, Mioclear, Ocuvite, ScoutPro, XIIDRA, Vyzulta, Lotemax, Prolensa, Minims, INFUSE, and many more.